{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:47:29Z","timestamp":1782200849955,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["EL2022.LNCC\/Na"],"award-info":[{"award-number":["EL2022.LNCC\/Na"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","award":["TCI 2024"],"award-info":[{"award-number":["TCI 2024"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08459-6","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T21:54:17Z","timestamp":1781733257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0324-2335","authenticated-orcid":false,"given":"Kathleen","family":"Ducoin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Goward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawuena","family":"Ahondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Lambot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Mordelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Daminette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morane","family":"Thabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Quereux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Khammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1407-6546","authenticated-orcid":false,"given":"Nathalie","family":"Labarri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"8459_CR1","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:5233\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8459_CR2","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1158\/1078-0432.CCR-10-0041","volume":"16","author":"MJ Besser","year":"2010","unstructured":"Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clin Cancer Res. 2010;16:2646\u201355.","journal-title":"Clin Cancer Res"},{"key":"8459_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cellimm.2011.12.004","volume":"273","author":"N Junker","year":"2012","unstructured":"Junker N, Kvistborg P, K\u00f8llgaard T, Straten P, thor, Andersen MH, Svane IM. Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. Cell Immunol. 2012;273:1\u20139.","journal-title":"Cell Immunol"},{"key":"8459_CR4","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","volume":"319","author":"SA Rosenberg","year":"1988","unstructured":"Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319:1676\u201380.","journal-title":"N Engl J Med"},{"key":"8459_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med Mass Med Soc. 2015;373:23\u201334.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"8459_CR6","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10:e005755.","journal-title":"J Immunother Cancer"},{"key":"8459_CR7","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, Borch TH, van den Berg JH, Met \u00d6, Kessels R, Geukes Foppen MH, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. N Engl J Med Mass Med Soc. 2022;387:2113\u201325.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"8459_CR8","doi-asserted-by":"publisher","first-page":"9505","DOI":"10.1200\/JCO.2024.42.16_suppl.9505","volume":"42","author":"SS Thomas","year":"2024","unstructured":"Thomas SS, Gogas H, Hong YK, In GK, De Doger B, Furness AJS, et al. Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. J Clin Oncol. 2024;42:9505\u20139505.","journal-title":"J Clin Oncol"},{"key":"8459_CR9","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1158\/1078-0432.CCR-17-3649","volume":"24","author":"M-A Forget","year":"2018","unstructured":"Forget M-A, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, et al. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018;24:4416\u201328.","journal-title":"Clin Cancer Res"},{"key":"8459_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1479-5876-10-169","volume":"10","author":"E Ellebaek","year":"2012","unstructured":"Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met \u00d6, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10:169.","journal-title":"J Transl Med"},{"key":"8459_CR11","doi-asserted-by":"publisher","first-page":"5317","DOI":"10.1158\/1078-0432.CCR-22-2103","volume":"28","author":"MS Hall","year":"2022","unstructured":"Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, et al. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022;28:5317\u201329.","journal-title":"Clin Cancer Res"},{"key":"8459_CR12","unstructured":"Chiffelle J, Barras D, P\u00e9tremand R, Orcurto A, Bobisse S, Arnaud M, et al. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity [Internet]. 2024 [cited 2024 Sep 23]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1074761324004138."},{"key":"8459_CR13","doi-asserted-by":"publisher","first-page":"2546402","DOI":"10.1080\/2162402X.2025.2546402","volume":"14","author":"M Hasanov","year":"2025","unstructured":"Hasanov M, Kiany S, Forget M-A, Bassett R, Davies MA, Diab A, et al. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology. 2025;14:2546402.","journal-title":"Oncoimmunology"},{"key":"8459_CR14","doi-asserted-by":"publisher","first-page":"e150535","DOI":"10.1172\/JCI150535","volume":"132","author":"NP Kristensen","year":"2022","unstructured":"Kristensen NP, Heeke C, Tvingsholm SA, Borch A, Draghi A, Crowther MD, et al. Neoantigen-reactive CD8\u2009+\u2009T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. J Clin Invest. 2022;132:e150535.","journal-title":"J Clin Invest"},{"key":"8459_CR15","doi-asserted-by":"publisher","first-page":"e001631","DOI":"10.1136\/jitc-2020-001631","volume":"8","author":"S Simon","year":"2020","unstructured":"Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, et al. PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy. J Immunother Cancer BMJ Specialist Journals. 2020;8:e001631.","journal-title":"J Immunother Cancer BMJ Specialist Journals"},{"key":"8459_CR16","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1172\/JCI73639","volume":"124","author":"A Gros","year":"2014","unstructured":"Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246\u201359.","journal-title":"J Clin Invest"},{"key":"8459_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/eji.1830200417","volume":"20","author":"N Gervois","year":"1990","unstructured":"Gervois N, Heuze F, Diez E, Jotereau F. Selective expansion of a specific anti-tumor CD8\u2009+\u2009cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol. 1990;20:825\u201331.","journal-title":"Eur J Immunol"},{"key":"8459_CR18","doi-asserted-by":"publisher","first-page":"btaf514","DOI":"10.1093\/bioinformatics\/btaf514","volume":"41","author":"J Deng","year":"2025","unstructured":"Deng J, Zhang J, Tian S, DiCarlo J, Xu H, Rulli SJ, et al. UMI-nea: a fast, robust tool for reference-free UMI deduplication and accurate quantification. Bioinformatics. 2025;41:btaf514.","journal-title":"Bioinformatics"},{"key":"8459_CR19","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1093\/bioinformatics\/btv309","volume":"31","author":"L Kuchenbecker","year":"2015","unstructured":"Kuchenbecker L, Nienen M, Hecht J, Neumann AU, Babel N, Reinert K, et al. IMSEQ\u2014a fast and error aware approach to immunogenetic sequence analysis. Bioinformatics. 2015;31:2963\u201371.","journal-title":"Bioinformatics"},{"key":"8459_CR20","doi-asserted-by":"crossref","unstructured":"Satopaa V, Albrecht J, Irwin D, Raghavan B. Finding a Kneedle in a Haystack: Detecting Knee Points in System Behavior. 2011 31st Int Conf Distrib Comput Syst Workshop [Internet]. 2011 [cited 2026 Feb 26]:166\u201371. Available from: https:\/\/ieeexplore.ieee.org\/document\/5961514.","DOI":"10.1109\/ICDCSW.2011.20"},{"key":"8459_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10616-010-9286-9","volume":"62","author":"MC Pandolfino","year":"2010","unstructured":"Pandolfino MC, Sa\u00efagh S, Knol AC, Dr\u00e9no B. Comparison of three culture media for the establishment of melanoma cell lines. Cytotechnology. 2010;62:403\u201312.","journal-title":"Cytotechnology"},{"key":"8459_CR22","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"8459_CR23","doi-asserted-by":"crossref","unstructured":"Duhen T, Duhen R, Montler R, Moses J, Moudgil T, De Miranda NF, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9.","DOI":"10.1038\/s41467-018-05072-0"},{"key":"8459_CR24","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","volume":"30","author":"U Dafni","year":"2019","unstructured":"Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Ann Oncol. 2019;30:1902\u201313.","journal-title":"Ann Oncol"},{"key":"8459_CR25","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1200\/JCO-25-00765","volume":"43","author":"T Medina","year":"2025","unstructured":"Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, et al. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. J Clin Oncol Wolters Kluwer. 2025;43:3565\u201372.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"8459_CR26","doi-asserted-by":"publisher","unstructured":"Coppola G, Kerr S, Cha P-C, Bersenev A, Olino K, Kluger HM, et al. Ex vivo expansion of melanoma tumor infiltrating lymphocytes leads to a dominant exhausted T cell population with lack of memory markers. Cancer Immunol Res [Internet]. 2026 [cited 2026 Feb 26]. Available from: https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0798.","DOI":"10.1158\/2326-6066.CIR-25-0798"},{"key":"8459_CR27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00262-002-0313-3","volume":"51","author":"N Labarri\u00e8re","year":"2002","unstructured":"Labarri\u00e8re N, Pandolfino M-C, Gervois N, Khammari A, Tessier M-H, Dr\u00e9no B, et al. Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother. 2002;51:532\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"8459_CR28","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1200\/JCO.2012.46.6441","volume":"31","author":"ME Dudley","year":"2013","unstructured":"Dudley ME, Gross CA, Somerville RPT, Hong Y, Schaub NP, Rosati SF, et al. Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. J Clin Oncol Wolters Kluwer. 2013;31:2152\u20139.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"8459_CR29","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clin Cancer Res. 2016;22:3734\u201345.","journal-title":"Clin Cancer Res"},{"key":"8459_CR30","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","volume":"28","author":"ST Levi","year":"2022","unstructured":"Levi ST, Copeland AR, Nah S, Crystal JS, Ivey GD, Lalani A, et al. Neoantigen Identification and Response to Adoptive Cell Transfer in anti PD-1 Na\u00efve and Experienced Patients with Metastatic Melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28:3042\u201352.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"8459_CR31","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med. 2016;375:2255\u201362.","journal-title":"N Engl J Med"},{"key":"8459_CR32","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41587-021-01072-6","volume":"40","author":"M Arnaud","year":"2022","unstructured":"Arnaud M, Chiffelle J, Genolet R, Navarro Rodrigo B, Perez MAS, Huber F, et al. Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nat Biotechnol. 2022;40:656\u201360.","journal-title":"Nat Biotechnol"},{"key":"8459_CR33","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N, Huq LM, Seitter SJ, Kim SP, Gartner JJ, Sindiri S, et al. Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes. J Clin Oncol Wolters Kluwer. 2022;40:1741\u201354.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"8459_CR34","doi-asserted-by":"publisher","first-page":"e008645","DOI":"10.1136\/jitc-2023-008645","volume":"12","author":"N Levin","year":"2024","unstructured":"Levin N, Kim SP, Marquardt CA, Vale NR, Yu Z, Sindiri S, et al. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes. J Immunother Cancer. 2024;12:e008645.","journal-title":"J Immunother Cancer"},{"key":"8459_CR35","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","volume":"7","author":"M Bassani-Sternberg","year":"2016","unstructured":"Bassani-Sternberg M, Br\u00e4unlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun Nat Publishing Group. 2016;7:13404.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"8459_CR36","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1158\/1078-0432.CCR-18-2722","volume":"25","author":"S Stevanovi\u0107","year":"2019","unstructured":"Stevanovi\u0107 S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, et al. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:1486\u201393.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"8459_CR37","doi-asserted-by":"publisher","first-page":"e000848","DOI":"10.1136\/jitc-2020-000848","volume":"8","author":"JH van den Berg","year":"2020","unstructured":"van den Berg JH, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8:e000848.","journal-title":"J Immunother Cancer"},{"key":"8459_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03704-y","volume":"596","author":"G Oliveira","year":"2021","unstructured":"Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick DT, Le PM, et al. Phenotype, specificity and avidity of antitumour CD8\u2009+\u2009T cells in melanoma. Nature. 2021;596:119\u201325.","journal-title":"Nature"},{"key":"8459_CR39","doi-asserted-by":"publisher","first-page":"7279","DOI":"10.1038\/s41467-025-62263-2","volume":"16","author":"M Maffezzini","year":"2025","unstructured":"Maffezzini M, Musio S, Di Ianni N, Rumolo A, Patan\u00e8 M, Galluzzo A, et al. Polyclonal expansion of functional tumor-reactive lymphocytes infiltrating glioblastoma for personalized cell therapy. Nat Commun Nat Publishing Group. 2025;16:7279.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"8459_CR40","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17:4550\u20137.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"8459_CR41","doi-asserted-by":"publisher","first-page":"100113","DOI":"10.1016\/j.iotech.2022.100113","volume":"16","author":"J Stoltenborg Granh\u00f8j","year":"2022","unstructured":"Stoltenborg Granh\u00f8j J, Rohaan M, Holz Borch T, Presti M, Nijenhuis C, van Zon M, et al. 8P Phenotypic characterization of infused tumor-infiltrating lymphocytes (TIL) correlates with response to adoptive cellular therapy (ACT) in patients with metastatic melanoma (MM). Immuno-Oncol Technol. 2022;16:100113.","journal-title":"Immuno-Oncol Technol"},{"key":"8459_CR42","doi-asserted-by":"publisher","first-page":"2538684","DOI":"10.1080\/2162402X.2025.2538684","volume":"14","author":"E Dupr\u00e9","year":"2025","unstructured":"Dupr\u00e9 E, Guiho A, Beauvais T, Labous L, Cardon T, Bertolotto C, et al. Systematic identification of lincRNA-derived immunogenic peptides in melanoma. Oncoimmunology. 2025;14:2538684.","journal-title":"Oncoimmunology"},{"key":"8459_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1084\/jem.20042138","volume":"202","author":"E Godefroy","year":"2005","unstructured":"Godefroy E, Moreau-Aubry A, Diez E, Dreno B, Jotereau F, Guilloux Y. \u03b1v\u03b23-dependent cross-presentation of matrix metalloproteinase\u20132 by melanoma cells gives rise to a new tumor antigen. J Exp Med. 2005;202:61\u201372.","journal-title":"J Exp Med"},{"key":"8459_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41586-025-09754-w","volume":"649","author":"S Ib\u00e1\u00f1ez-Molero","year":"2026","unstructured":"Ib\u00e1\u00f1ez-Molero S, Veldman J, Simon Nieto J, Traets JJH, George A, Hoefakker K, et al. Tumour-reactive heterotypic CD8 T cell clusters from clinical samples. Nature. 2026;649:467\u201376.","journal-title":"Nature"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08459-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:03:25Z","timestamp":1782198205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8459"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08459-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All information for human data and mice experiments are available in the Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"800"}}